Abstract 224P
Background
Maximal heterozygosity on the human leukocyte antigen (HLA) loci was found to be associated with improved survival among NSCLC patients treated with immune checkpoint inhibitors (ICI). Here we aimed to investigate the effect of germline HLA-I/-II zygosity on clinical outcomes among NSCLC patients treated with first-line pembrolizumab in combination with chemotherapy. We explored the correlation between different HLA-A/-B supertypes and clinical outcome among the same cohort.
Methods
We prospectively collected pre-treatment blood from patients with NSCLC treated with first-line pembrolizumab in combination with chemotherapy. DNA was extracted from white blood cells and used for high resolution HLA-I/II typing. Genomic HLA-I/II homozygosity was correlated with clinical benefit. We used Sidney et al to classify genomic HLA-A and -B into supertypes.
Results
Of 65 patients recruited, 53 complied with the inclusion criteria. Of those 76%(40/53) have PD-L1 expression of <50% of their cancer cells. Our analysis did not find any association between HLA-I/-II homozygosity and clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy. However, the absence of HLA-A01 was associated with favourable PFS (HR=2.09, 95%CI 1.03-4.27, P=0.22) and improved OS (HR=2.58, 95%CI 0.96-6.89, P=0.038). the presence of HLA-B27 was associated with improved PFS (HR=0.24, 95%CI 0.12, P=0.004) but not OS.
Conclusions
The absence of association between genomic HLA-I/-II homozygosity and clinical outcome among patients with advanced NSCLC treated with pembrolizumab in combination with chemotherapy might reflect a diminished role for HLA molecules among patients with low or no PD-L1. HLA-A01 and HLA-B27 might have a role in predicting clinical outcome among this cohort of patients. Further studies are needed to explore biomarkers for this group of patients.
Clinical trial identification
NA
Editorial acknowledgement
Nil
Legal entity responsible for the study
The authors.
Funding
Higher degree by research award scheme provided by Centre for Precision Health at ECU.
Disclosure
M. Millward: Financial Interests, Personal, Advisory Board: BeiGene Australia Pty Ltd, Bristol Myers Squibb Australia Pty Ltd, AstraZeneca Australia Pty Ltd, The Limbic, Eli Lilly Australia Pty Ltd, IQVIA Australia Pty Ltd, Amgen Australia Pty Ltd, Merck Pte Ltd, Pfizer Australia Pty Ltd, Guardant Health, Roche Products Pty Ltd; Financial Interests, Personal, Full or part-time Employment, Employee: University of Western Australia; Financial Interests, Personal, Other, Consultant: Linear Clinical Research; Financial Interests, Institutional, Local PI, Trial payments to Institution: Bristol Myers Squibb, Genentech/Roche, BeiGene, Eli Lilly, Albion Laboratories, Akeso Biopharma, AbbVie, Five Prime Therapeutics, Dizal Pharma, Maxinovel, Amgen, Atridia, INXMED, Alpine Immune Sciences, Turning Point Therapeutics, IMPACT Therapeutics, Kinnate Biopharma, Rely Therapeutics, GenFleet Therapeutics, Vivace Therapeutics, Eucure Biopahrma, InventisBio, Cullinan Oncology, Tyra Biosciences, Axelia Oncology; Non-Financial Interests, Other, Scientific Advisory Committee member: Thoracic Oncology Group Australasia. E.S. Gray: Financial Interests, Personal, Invited Speaker, Invited to present at an MSD event in Melbourne, Australia: MSD Discovery Research Symposium, 28-29th October 2019, Melbourne, Victoria. “Liquid Biopsy for Predicting and Monitoring Response to Immune Checkpoint Blockade in Metastatic Melanoma Patients”: MSD; Financial Interests, Personal, Invited Speaker, Invited to present on a industry sponsored session at ESMO 2022European Society of Medical Oncology, 9-13th September 2022, Paris, France. “Circulating tumour DNA in patients with advanced ovarian cancer receiving neoadjuvant chemo-immunotherapy”: Thermo Fisher Scientific; Financial Interests, Institutional, Research Grant, Grant recipient for the following project:TCR repertoire in combination with HLA and TMB as predictor of response to immune checkpoint blockade in melanoma and lung cancer. Thermo Fisher Scientific Oncomine Clinical Research Grant. 2021. $200,000: Thermo Fisher Scientific. All other authors have declared no conflicts of interest.
Resources from the same session
155P - Exploring the utility of serum anti-tNASP antibodies as a screening biomarker in prostate, pancreatic, and ovarian cancer
Presenter: Oleg Alekseev
Session: Poster session 01
156P - The association between fibrotic endotypes, determined by pre-treatment serum levels of collagen metabolites, and survival outcomes in patients with pancreatic cancer
Presenter: Rasmus Pedersen
Session: Poster session 01
157P - CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer
Presenter: Pengfei Yu
Session: Poster session 01
158P - In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas
Presenter: Arturo Gonzalez-Vilanova
Session: Poster session 01
159P - Better performance of pan-claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody
Presenter: Shujuan NI
Session: Poster session 01
161P - Biomarkers of neoadjuvant combinational therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
Presenter: Yue Wang
Session: Poster session 01
162P - MR imaging biomarkers profiles in patients with prostate cancer treated with androgen deprivation therapy
Presenter: Angel Luis Sanchez Iglesias
Session: Poster session 01
163P - Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors
Presenter: Jair Bar
Session: Poster session 01
164P - Early evaluation of effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
Presenter: Astrid Kramer
Session: Poster session 01